PATH vs STXS · P/E 19, rev $1.61B vs rev $26.9M
Uipath Inc (PATH) versus Stereotaxis Inc (STXS) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Stereotaxis Inc (STXS) is a medical instruments & supplies company listed on AMEX.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported STXS revenue for 2024-12-31 was $26.9M. Net income was -$24.0M. Revenue was up 0.5% from 2023-12-31 to 2024-12-31. STXS currently screens at market cap $174.0M.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. STXS currently screens at market cap $174.0M.
Not investment advice. Open the PATH and STXS stock pages for the full models.
Not investment advice.